2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1157

Peptidylarginine Deiminase Inhibition Prevents Neutrophil Extracellular Trap Formation, Modulates Innate Immune Responses, and Reduces Vascular Damage In Mice
Abstract Number: 1965

Performance Of a Computer-Based Method To Measure Erosions In Rheumatoid Arthritis: A Longitudinal Study
Abstract Number: 1367

Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
Abstract Number: 2826

Performance Of Five Current Risk Algorithms In Predicting Cardiovascular Events In Rheumatoid Arthritis Patients
Abstract Number: 1994

Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In a Longitudinal Observational Study Of Patients With Gout
Abstract Number: 2656

Performance Of Prediction Models For Rheumatoid Arthritis Serologic Phenotypes Among Women Using Family History, Genetics and Environmental Factors
Abstract Number: 2282

Performance Of The 2010 ACR/EULAR Classification Criteria For Rheumatoid Arthritis In a Group Of Elderly Onset Patients
Abstract Number: 1131

Peri-Articular Fractal Signature Analysis and Bone Mineral Density Measure Different Aspects Of Bone: Cross-Sectional Data From The Osteoarthritis Initiative
Abstract Number: 2483

Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Abstract Number: 1746

Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Abstract Number: 1059

Perinatal and Early Life Risk Factors For Systemic Lupus Erythematosus In a National Cohort Of Women
Abstract Number: 2043

Perinatal Exposure To Traditional and Biologic Disease Modifying Antirheumatic Drugs In Rheumatic Diseases: A Systematic Review Of Congenital Outcomes
Abstract Number: 1060

Perinatal Risk Factors For Systemic Lupus: A Register-Based Case-Control Study
Abstract Number: 2476

Periodontal Disease Is Not Associated With Ankylosing Spondylitis and TNF-Alpha Blockers Usage In Korea
Abstract Number: 807

Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].